Hugel: Shares Down Sharply Over Past Year While Margins and Returns Stay High

Thesis

The data shows a clear split between the share price and the reported numbers. The price fell 22.1% in one month, 26.5% in three months and 34.5% in one year, and it sits 41.7% below the 52-week high of ₩308,500. Over the same period the filed financials show growing revenue, operating margins above 40% and ROE of 17.0%. The data does not explain the price decline. No news headlines, investor flow data, foreign ownership or short balance figures are available, so the cause cannot be identified from this dataset. The numbers support a business that is profitable and financially conservative. They do not show what is driving investor sentiment, and they say nothing about future earnings.

Business overview

Hugel is listed on KOSDAQ in the Biotech & Pharma sector. It was founded on 2001-11-22 and listed on 2015-12-24. The CEO is Doohyun Chang. It has 12,604,033 listed shares and a market capitalisation of about ₩2.27T. Enterprise value is about ₩2.01T, which is lower than market cap because of its net cash position. Annual revenue rose from ₩245.2B in 2021 to ₩425.1B in 2025. The dataset does not describe products or segments, so nothing more is stated here.

Financial analysis

All figures come from filed financial statements (DART). Revenue grew every year shown: 13.5% in 2023, 16.7% in 2024 and 14.0% in 2025, reaching ₩425.1B. Operating income rose from ₩97.2B in 2021 to ₩200.9B in 2025, and operating margin moved from 36.0% in 2022 to 47.2% in 2025. Net income was ₩140.9B in 2025, up from ₩57.7B in 2021. ROE improved from 7.4% in 2021 to 16.1% in 2025. For the trailing twelve months to H1 2026, revenue was ₩479.6B, operating income ₩208.9B (43.6% margin) and net income ₩158.0B (32.9% margin). The TTM operating margin is below the 2025 level of 47.2%. ROE was 17.0%. Liabilities to equity were 9.6%, cash was ₩259.6B and free cash flow was ₩148.3B. Borrowings data is not available.

Valuation

The current P/E is 14.4, versus 20.6 at the end of 2025. P/B is 2.2, versus 3.1 at the end of 2025. P/S is 4.7. Dividend yield is 0.0%. EV/EBITDA is not available, and year-end multiples for earlier years are not available, so the comparison to its own history only covers 2025. Among the peers listed, P/E ratios are 43.1 for Samsung Biologics, 25.5 for Celltrion, 63.9 for Alteogen and 28.0 for Hanmi Pharm. HLB has no P/E. P/B ratios are 10.2, 2.2, 23.0, 4.3 and 16.9 respectively. Hugel's P/E is the lowest of those with a figure, and its P/B equals Celltrion's. The peers are much larger and differ in business, so the comparison is only a rough guide.

Catalysts

• The half-year report for June 2026, filed on 2026-08-14, showed trailing profit margins that remain high.
• Three investor relations events were filed on 2026-09-07, 2026-09-14 and 2026-09-30, indicating active communication with investors.
• Extraordinary shareholder meeting results were filed on 2026-08-21 and amended on 2026-08-24, alongside a filing about independent director appointments or departures.
• Insider shareholding reports were filed on 2026-08-21, 2026-09-09 and 2026-09-30, though the data does not show the direction of any changes.

Risks

• The share price is near its 52-week low after falling 34.5% in a year, and the data offers no explanation for the move.
• The TTM operating margin of 43.6% is below the 47.2% reported for 2025, which could signal margin pressure if the trend continues.
• Investor flow, foreign ownership and short balance data are unavailable, so selling pressure cannot be assessed.
• No dividend is paid, so shareholder returns depend entirely on the share price.
• The dataset contains no news headlines or guidance, which limits visibility into business developments.

Closing view

The filed numbers show steady revenue growth, high margins, strong cash generation and very low leverage, and the P/E of 14.4 is lower than the 20.6 at the end of 2025 and below the peers that report one. The share price has fallen sharply, and the data cannot say why. The slight decline in the TTM margin and the lack of flow and news data leave open questions. The evidence points to a financially sound company whose market valuation has moved sharply lower, without enough information to explain that move.

Model estimate of fair value

The valuation model has no estimate for this company yet (not enough data, or no positive value with the base case).

Report history

1. Oct 13, 2026InitiationHugel: Shares Down Sharply Over Past Year While Margins and Returns Stay High